[Featured Stock] Dawonsys Anticipates Record Sales... Success in Medical Accelerator New Business

[Asia Economy Reporter Hyungsoo Park] Dawonsys is showing strong performance. The management goal of achieving the highest-ever sales this year appears to have influenced the stock price.

As of 1:58 PM on the 15th, Dawonsys is trading at 17,100 KRW, up 6.88% from the previous day.

Through its earnings forecast disclosure, Dawonsys expects to achieve sales of 300 billion KRW based on separate financial statements this year.

Dawonsys reached an order backlog of approximately 1 trillion KRW in 2019, including the supply of EMU-150 railway vehicles. The order volume is growing rapidly. In overseas business, the company has entered the Indian and Myanmar markets, raising expectations for diversification of sales channels.

A company official stated, “Thanks to last year's record-high order performance and overall strong business conditions, we expect stable and steep growth going forward.” He added, “This year, we will break the record with sales of 300 billion KRW and take a step forward.”

The official also expressed ambitions, saying, “This year, along with growth in existing business sales, we anticipate a step forward in new businesses such as the clinical progress and IPO promotion of the medical accelerator business (A-BNCT) being conducted by our subsidiary Dawon Medax.” He further introduced, “We plan to reveal this year’s and mid-to-long-term growth vision at the Vision 2030 proclamation ceremony to be held at 'The K Hotel Seoul' on the 17th.”